mhurhangee/patent-ind-claim-en huggingface dataset:
A fault clearing method in a flexible DC converter station comprising a flexible DC converter station respectively configured with a grid side switch (QF1) and a valve side phase-split switch (QF2), and when a fault occurs in the converter station, firstly tripping a valve side non-faulty phase switch, then tripping the grid side switch, and performing the clearing for faults in the converter station, the clearing method is characterised in that it includes: recognizing, by a protection system, a faulty phase and a non-faulty phase when a fault occurs in the converter station; sending a non-faulty phase valve side switch (QF2) trip command at time t1, and sending a grid side switch (QF1) trip command at time t2, wherein the relationship between t1 and t2 is t1<t2; sending a faulty phase valve side switch (QF2) trip command after a time interval Δt, after tripping the grid side switch (QF1). recognizing, by a protection system, a faulty phase and a non-faulty phase when a fault occurs in the converter station; sending a non-faulty phase valve side switch (QF2) trip command at time t1, and sending a grid side switch (QF1) trip command at time t2, wherein the relationship between t1 and t2 is t1<t2; sending a faulty phase valve side switch (QF2) trip command after a time interval Δt, after tripping the grid side switch (QF1).
A method of regenerating hydrogenation catalyst activity in-situ in the processing of sugars or polysaccharides, the method comprising: a) providing a continuous feed hydrogenation reactor containing a catalyst, said reactor being configured to have a first and a second vessel, each vessel respectively having a first catalyst and a second catalyst, the catalysts being either the same or of a different material; and b) rinsing each respective vessel and catalyst with subcritical deionized water of between 130°C-250°C for an extended period. a) providing a continuous feed hydrogenation reactor containing a catalyst, said reactor being configured to have a first and a second vessel, each vessel respectively having a first catalyst and a second catalyst, the catalysts being either the same or of a different material; and b) rinsing each respective vessel and catalyst with subcritical deionized water of between 130°C-250°C for an extended period.
Elastomer composition comprising an elastomer matrix and mixed therein a precursor for a fluid-soluble compound, which precursor has limited solubility in a fluid of 10 -4 M or less and which may be converted into a compound that is soluble in said fluid, such that said conversion of the precursor into the fluid-soluble compound renders the composition fluid-swellable.
A cleaning tool comprising: a head part to which a member for cleaning is attached; and a handle part connected to the head part and for being gripped by a user, wherein the head part includes a top surface part forming an upper surface side, to which the handle part is connected and a bottom surface part forming a lower surface side, and the bottom surface part is formed to be freely attachable/detachable with respect to the top surface part, characterized in that the center of gravity is positioned in a part (Q1) close to the head part when the handle part is divided into two in a longitudinal direction in a state where the handle part is horizontally laid down both in a state where the bottom surface part is attached to the top surface part and a state where the bottom surface part is not attached to the top surface part. a head part to which a member for cleaning is attached; and a handle part connected to the head part and for being gripped by a user, wherein the head part includes a top surface part forming an upper surface side, to which the handle part is connected and a bottom surface part forming a lower surface side, and the bottom surface part is formed to be freely attachable/detachable with respect to the top surface part, characterized in that the center of gravity is positioned in a part (Q1) close to the head part when the handle part is divided into two in a longitudinal direction in a state where the handle part is horizontally laid down both in a state where the bottom surface part is attached to the top surface part and a state where the bottom surface part is not attached to the top surface part.
A compound, or a pharmaceutically-acceptable salt thereof, selected from the group consisting of: 5-(2-ethyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(2-isopropyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(2-ethyl-5-methyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(2-propyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(2-vinyl-2,3-dihydro-1 H -inden-2-yl)-1 H- imidazole, 5-(2-(prop-1-en-2-yl)-2,3-dihydro-1 H- inden-2-yl)-1 H- imidazole, 5-(2-allyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(2-butyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(2,5-dimethyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole,5-(2-ethyl-5-fluoro-2,3-dihydro-1 H- inden-2-yl)-1 H- imidazole, 5-(5-chloro-2-ethyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 2-(1 H -imidazol-5-yl)-2-methyl-2,3-dihydro-1 H -inden-5-amine, (2-(1 H -imidazol-5-yl)-2,3-dihydro-1 H -inden-2-yl)methanol, 1-(2-(1 H -imidazol-5-yl)-2,3-dihydro-1 H -inden-2-yl)ethanol, 2-(2-(1 H -imidazol-5-yl)-2,3-dihydro-1 H -inden-2-yl)propan-2-ol, 2-(1 H -imidazol-5-yl)-2,3-dihydro-1 H -indene-2-carbonitrile, 5-(5-fluoro-2-methyl-2,3-dihydro-1 H -inden-2-yl)-1 H- imidazole, 5-(5,6-dichloro-2-ethyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(5-chloro-2-ethyl-6-fluoro-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(2-ethyl-5,6-difluoro-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 2-ethyl-6-fluoro-2-(1 H -imidazol-5-yl)-2,3-dihydro-1 H -inden-5-amine, 5-(2-ethyl-5-nitro-2,3-dihydro-1 H- inden-2-yl)-1 H- imidazole, 5-(2-(methoxymethyl)-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 5-(5-methyl-2,3-dihydro-1 H -inden-2-yl)-1 H -imidazole, 1-(2-(1 H -imidazol-5-yl)-2,3-dihydro-1 H -inden-2-yl)ethanone, 5-(2,3-dihydro-1-methyl-1H-inden-1-yl)-1 H -imidazole, 5-(1,2,3,4-tetrahydronaphthalen-2-yl)-1H-imidazole, and 5-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-imidazole, for use for producing local or regional anesthesia or analgesia in a nerve or tissue containing an axon or nerve fiber.
An electrosurgical device for directing energy to a target volume of tissue, comprising: a coaxial feedline having an inner conductor , an outer conductor coaxially disposed around the inner conductor, and a dielectric material disposed therebetween ; an elongated electrically-conductive member longitudinally disposed at a distal end of the inner conductor; a balun disposed in association with the outer conductor, and comprising a dielectric layer coaxially disposed around a distal portion of the outer conductor, and an electrically-conductive layer coaxially disposed around a proximal portion of the dielectric layer; an electrically-conductive cylinder including a first portion coaxially disposed around a distal portion of the electrically conductive layer of the balun; and a second portion disposed distally to the first portion, wherein the second portion distally extends beyond a distal end of the electrically-conductive layer of the balun; a dielectric structure disposed adjacent to a distal end of the electrically-conductive cylinder, wherein the dielectric structure longitudinally extends from the distal end of the electrically-conductive cylinder to a distal end of the electrically-conductive member . a coaxial feedline having an inner conductor , an outer conductor coaxially disposed around the inner conductor, and a dielectric material disposed therebetween ; an elongated electrically-conductive member longitudinally disposed at a distal end of the inner conductor; a balun disposed in association with the outer conductor, and comprising a dielectric layer coaxially disposed around a distal portion of the outer conductor, and an electrically-conductive layer coaxially disposed around a proximal portion of the dielectric layer; an electrically-conductive cylinder including a first portion coaxially disposed around a distal portion of the electrically conductive layer of the balun; and a second portion disposed distally to the first portion, wherein the second portion distally extends beyond a distal end of the electrically-conductive layer of the balun; a dielectric structure disposed adjacent to a distal end of the electrically-conductive cylinder, wherein the dielectric structure longitudinally extends from the distal end of the electrically-conductive cylinder to a distal end of the electrically-conductive member .
A compound of formula or a salt, or ester thereof for use in the treatment of pain, wherein the treatment comprises administration of a therapeutically effective amount of the compound to a patient in need thereof, wherein the pain is selected from the group consisting of: acute pain, chronic pain, and inflammatory pain.
A three-dimensional printing system comprising a print head vertically arranged above a build platform, said print head having a variable-width nozzle with a rectangular opening having a size, a means of moving said print-head and a means for directly extruding pellets through said variable-width nozzle to provide a molten ribbon vertically above said build platform, said pellets comprising at least one polymer, said extrusion means incorporating a heated chamber before said nozzle and said variable-width nozzle incorporating an actively controlled gate, wherein said actively controlled gate controls the nozzle opening in one dimension, while the other dimension remains fixed, and wherein said variable-width nozzle is axially rotatable.
Fastening element configured to be installed in a mobile device for the maintenance of land, in particular turfgrasses or gardens or agricultural land, said fastening element comprising: - at least one main body , - at least a first groove extending from an inner area of the main body to a peripheral area of the main body itself where a first opening for access to the first groove is defined, - at least a second groove distinct and spaced from the first groove , said second groove extending from the inner area of the main body towards the peripheral area of the main body itself where a second opening for access to the second groove is defined, wherein the first groove extends from the first opening for at least a first stretch, along a straight trajectory (X), characterised in that the second groove has: - at least a first stretch extending from the second opening , transversely to the trajectory (X) of the first groove , - at least a second stretch extending in continuation of the first stretch, along a direction parallel to, or coinciding with, the trajectory (X). - at least one main body , - at least a first groove extending from an inner area of the main body to a peripheral area of the main body itself where a first opening for access to the first groove is defined, - at least a second groove distinct and spaced from the first groove , said second groove extending from the inner area of the main body towards the peripheral area of the main body itself where a second opening for access to the second groove is defined, wherein the first groove extends from the first opening for at least a first stretch, along a straight trajectory (X), characterised in that the second groove has: - at least a first stretch extending from the second opening , transversely to the trajectory (X) of the first groove , - at least a second stretch extending in continuation of the first stretch, along a direction parallel to, or coinciding with, the trajectory (X). - at least a first stretch extending from the second opening , transversely to the trajectory (X) of the first groove , - at least a second stretch extending in continuation of the first stretch, along a direction parallel to, or coinciding with, the trajectory (X).
Method for actuating a thermoelectric two-point drive of a valve of a temperature-control-medium-operated heating and/or cooling system e.g. of a building, in particular a radiant heating and/or cooling system, wherein, in the method, - the two-point drive is actuated by an electrical actuation signal, the magnitude of which is set on the basis of a currently desired flow rate of the temperature-control medium to a value between a minimum value at which the valve is completely closed and a maximum value at which the valve is completely open, inclusive, - the two-point drive is actuated sequentially by actuation signals of different magnitudes for determining a minimum opening position of the valve at which a predetermined minimum flow rate of the temperature-control medium is set and/or for determining a maximum opening position of the valve at which a predetermined maximum flow rate or the maximum flow rate of the temperature-control medium is set, - a sensor arranged in the heating and/or cooling system emits a measuring signal that represents the flow rate of the temperature-control medium resulting from the actuation of the two-point drive and thus the setting of the valve, and - the actuation signal or signals for the two-point drive which is/are assigned to the minimum flow rate and/or the maximum flow rate is/are stored. - the two-point drive is actuated by an electrical actuation signal, the magnitude of which is set on the basis of a currently desired flow rate of the temperature-control medium to a value between a minimum value at which the valve is completely closed and a maximum value at which the valve is completely open, inclusive, - the two-point drive is actuated sequentially by actuation signals of different magnitudes for determining a minimum opening position of the valve at which a predetermined minimum flow rate of the temperature-control medium is set and/or for determining a maximum opening position of the valve at which a predetermined maximum flow rate or the maximum flow rate of the temperature-control medium is set, - a sensor arranged in the heating and/or cooling system emits a measuring signal that represents the flow rate of the temperature-control medium resulting from the actuation of the two-point drive and thus the setting of the valve, and - the actuation signal or signals for the two-point drive which is/are assigned to the minimum flow rate and/or the maximum flow rate is/are stored.
A microporous film comprising a polymeric composition and a filler, wherein the film has an average water vapor transmission rate of at least about 16,000 grams H 2 O/24-hour/m 2 , a hydrostatic head pressure of at least about 300 mbar, and a basis weight of from about 5 gsm to about 50 gsm.
An assembly element , in particular for mounting to a building ceiling wall, for separating an interior space (I) from an exterior space (A), comprising - a stationary element with an end area , which, at least partially, is formed border-open front-sided in the direction of a building wall , - a wall connection for fastening the stationary element to the building wall , wherein the wall connection includes a first wall connection profile element (2.1) with at least one side wall part for receiving the end area and with a base wall part with a fastening opening for guiding through a first fastening means for fastening the first wall connection profile element (2.1) to the building wall , characterized by - a fastening element with a continuous mounting channel for guiding through a second fastening means , wherein, via the second fastening means , the fastening element is fastened to an inside located intermediate base in the end area of the stationary element , and - a side wall profile , which has a first fastening opening (2.2d) and, via a first connector means , which is guided through the first fastening opening (2.2d), is fastened to the base wall part of the first wall connection profile element (2.1), and which, via a second connector means , which is guided through a second fastening opening (2.2e), is fastened to the fastening element , which is inside-located disposed in the end area of the stationary element . - a stationary element with an end area , which, at least partially, is formed border-open front-sided in the direction of a building wall , - a wall connection for fastening the stationary element to the building wall , wherein the wall connection includes a first wall connection profile element (2.1) with at least one side wall part for receiving the end area and with a base wall part with a fastening opening for guiding through a first fastening means for fastening the first wall connection profile element (2.1) to the building wall , characterized by - a fastening element with a continuous mounting channel for guiding through a second fastening means , wherein, via the second fastening means , the fastening element is fastened to an inside located intermediate base in the end area of the stationary element , and - a side wall profile , which has a first fastening opening (2.2d) and, via a first connector means , which is guided through the first fastening opening (2.2d), is fastened to the base wall part of the first wall connection profile element (2.1), and which, via a second connector means , which is guided through a second fastening opening (2.2e), is fastened to the fastening element , which is inside-located disposed in the end area of the stationary element .
Method for determining the efficiency and specificity of the introduction of a nucleic acid into the genome of a mammalian cell, whereby the mammalian cell comprises one or two transcriptionally active alleles of a DPH1, DPH2, DPH4 and/or DPH5 gene, comprising the steps of - transfecting the mammalian cell with one or more plasmids comprising the nucleic acid to be introduced, a nucleic acid conferring resistance to a selection marker, and the elements required for gene editing of said DPH gene, - cultivating the transfected cell in the absence of selection pressure, - depositing the cells of the transfected multitude of cells as single cells, - cultivating a first number of single deposited cells in the presence of a DPH gene transcription sensitive toxin, and cultivating a second number of single deposited cells in the presence of the corresponding selection marker, - determining the number of toxin resistant colonies and the number of antibiotic resistant colonies, wherein the ratio between integration events represented by the number of antibiotic resistant colonies and inactivation events represented by the number of toxin resistant colonies reflects the specificity of the method. - transfecting the mammalian cell with one or more plasmids comprising the nucleic acid to be introduced, a nucleic acid conferring resistance to a selection marker, and the elements required for gene editing of said DPH gene, - cultivating the transfected cell in the absence of selection pressure, - depositing the cells of the transfected multitude of cells as single cells, - cultivating a first number of single deposited cells in the presence of a DPH gene transcription sensitive toxin, and cultivating a second number of single deposited cells in the presence of the corresponding selection marker, - determining the number of toxin resistant colonies and the number of antibiotic resistant colonies, wherein the ratio between integration events represented by the number of antibiotic resistant colonies and inactivation events represented by the number of toxin resistant colonies reflects the specificity of the method.
A method for determining whether a patient is likely to benefit from treatment with a therapeutic formulation, the method comprising the steps of: (a) determining the concentration of corticotropin releasing hormone (CRH) in a sample from a patient prior to administration of the therapeutic formulation; (b) determining the concentration of CRH in a sample from a patient subsequent to administration of the therapeutic formulation; and (c) comparing the concentration of CRH pre-administration with the concentration of CRH subsequent to administration; wherein an increase in patient CRH concentration subsequent to administration indicates that the patient is likely to benefit from treatment with the therapeutic formulation and wherein no increase or a decrease in patient CRH concentration subsequent to administration indicates that the patient is unlikely to benefit from treatment with the therapeutic formulation; wherein the therapeutic formulation comprises CRH. (a) determining the concentration of corticotropin releasing hormone (CRH) in a sample from a patient prior to administration of the therapeutic formulation; (b) determining the concentration of CRH in a sample from a patient subsequent to administration of the therapeutic formulation; and (c) comparing the concentration of CRH pre-administration with the concentration of CRH subsequent to administration;
A method for processing blockchain-based data, the method comprising: receiving , by a blockchain node, transaction data and formatted information corresponding to the transaction data, wherein the blockchain node is a node in a blockchain network; determining , by the blockchain node and based on a transaction type corresponding to the transaction data and a predetermined relationship between the transaction type and a processing policy, the processing policy corresponding to the transaction data, wherein the processing policy comprises a data attribute used for conversion and a conversion rule corresponding to the data attribute and wherein the formatted information comprises a sorting sequence included in the processing policy; converting , by the blockchain node, the formatted information into a first attribute value based on the conversion rule comprised in the processing policy; determining a data attribute corresponding to the first attribute value; and verifying , by the blockchain node, the received transaction data by comparing the first attribute value and a second attribute value of the determined data attribute in the transaction data, wherein, if the first attribute value and the second attribute value are the same, the verifying determines that the transaction data passes the verification. receiving , by a blockchain node, transaction data and formatted information corresponding to the transaction data, wherein the blockchain node is a node in a blockchain network; determining , by the blockchain node and based on a transaction type corresponding to the transaction data and a predetermined relationship between the transaction type and a processing policy, the processing policy corresponding to the transaction data, wherein the processing policy comprises a data attribute used for conversion and a conversion rule corresponding to the data attribute and wherein the formatted information comprises a sorting sequence included in the processing policy; converting , by the blockchain node, the formatted information into a first attribute value based on the conversion rule comprised in the processing policy; determining a data attribute corresponding to the first attribute value; and verifying , by the blockchain node, the received transaction data by comparing the first attribute value and a second attribute value of the determined data attribute in the transaction data, wherein, if the first attribute value and the second attribute value are the same, the verifying determines that the transaction data passes the verification.
A dialysis machine having an extracorporeal blood circuit , a dialyzate circuit , a dialyzer and a processing unit , wherein at least one sensor for determining a property of the dialyzate is arranged in the dialyzate circuit, characterized in that the processing unit is configured such that temporal evaluation ranges are fixed during an initial phase of the dialysis treatment, in which all stability criteria from a predefined group are satisfied, and in that only measured values determined by the at least one sensor within these temporal evaluations ranges are used for determining a pre-dialysis property of the patient's blood.